Tradestie Institutional Equity Comparison Engine

LXRX vs SANA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SANA Overall Edge

SANA Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sana Biotechnology, Inc. Common Stock (SANA) driven by superior Growth & Margin, Options & Structure while LXRX counters with relative strength in Momentum & Technical. Fundamentally, LXRX trades at N/M Forward P/E with -147.4% operating margin (-20.7% YoY revenue) versus SANA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LXRX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LXRX N/M vs SANA N/M Fwd P/E
Growth & Margin Winner SANA
Op Margin -147.4% vs 0.0% ยท YoY -20.7% vs +0.0%
Momentum & Technical Winner LXRX
1Y +21.5% vs -48.6% ยท 52W Pos 41% vs 1%
Options & Structure Winner SANA
BREAKDOWN (8th %ile IV) vs BREAKDOWN (4th %ile IV)
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.23% 1D
Market Cap $797.0M
1M Return +15.13%
1Y Return +21.53%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 5.0 Fund 33.0 Flow 65.0 Mom 44.0
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
1M Return -17.18%
1Y Return -48.63%
Forward P/E N/M
Unified AI Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LXRX +21.53% SANA -48.63% Spread: +70.16 pp (LXRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LXRX TTM Op. Margin: -147.4% SANA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LXRX vs SANA. Trailing 12-month operating profitability (LXRX -147.4% vs SANA 0.0%) and valuation multiples (LXRX N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LXRX (4) vs SANA (4)
Institutional Metric LXRX SANA Criterion Row Winner
Market Capitalization Scale $797.0M $605.3M Larger Scale LXRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -20.7% +0.0% Higher Growth SANA
Operating Margin (TTM) Profitability -147.4% 0.0% Higher Margin SANA
Net Profit Margin Profitability -161.8% 0.0% Higher Margin SANA
Return on Equity (ROE) Capital Efficiency -43.9% -79.5% Higher ROE LXRX
52-Week Range Position Momentum 41% ($1โ€“$3) 1% ($2โ€“$5) Stronger Trend LXRX
Beta / 30D Volatility Risk Regime 0.63ฮฒ ยท 60% Vol 1.82ฮฒ ยท 78% Vol Lower Realized Risk LXRX
Unified Institutional Score Composite Signal 38.7 / 100 (SELL) 44.3 / 100 (HOLD) Higher Composite SANA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LXRX vs SANA Buy Guide
LXRX BREAKDOWN
98d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live SANA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LXRX nor SANA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.